Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

University of Florida, Gainesville, and a lead investigator in this Phase IIb study.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treat
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Wrightington, Wigan ... Allscripts (NASDAQ: MDRX ) are delighted to ... as WWL,s new health information system. The system will ... completely transform the way WWL delivers healthcare in the ... a demonstrated record of on-time and on-budget system implementations ...
(Date:9/30/2014)... 30, 2014 This study provides an ... informatics solutions including nuclear imaging informatics, PET imaging ... study assesses the size of the market based ... and projects future growth based on the current ... taking place in the broader markets for imaging ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group ... in Brazil , Russia ... China (BRIC) will see robust expansion ... increasingly favored over surgical procedures. Although revenues will be ... reimbursement challenges, prolonged device approval times and demand for ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... Feb. 23, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Department of Defense (DOD) to provide remote service and support ... the DOD,s secure B2B gateway. Roche is the first in-vitro ... for this remote access. The B2B gateway is ...
... Feb. 23, 2011 Xenogenics Corporation ("Xenogenics"), a majority ... MCET), is pleased to announce it has retained the ... of its capital formation strategy to help finance expanded ... In animal testing and initial human use, the ...
Cached Medicine Technology:Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD 2Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 2Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 3Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 4
(Date:10/1/2014)... 2014 Woodland Hills dental ... group of dental specialists who treat full mouth implant ... of Oviedo. Dr. Reshad of the Anacapa Dental Art ... on two continents, will give a full-day presentation Oct. ... reconstruction. , “These specialists want to improve their skills ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Generic drug ... retail generics increasing in price in the last 12 ... Inc.’s (AIS) Drug Benefit News (DBN) interviewed a plan ... means for pharmacies and health plans. , “When ... rising generic acquisition costs, these cost increases squeeze pharmacies’ ...
(Date:10/1/2014)... insulin is safer and more effective than intermediate-acting ... to new research published in the BMJ ... twice-daily doses of both long- and intermediate-acting insulin, ... "In patients with Type 1 diabetes, we found ... when it came to controlling blood sugar, preventing ...
(Date:10/1/2014)... Looking for holiday gift ideas? Éminence Organic Skin ... giving easy this holiday season. Starting October 1st 2014, new ... all shopping dilemmas. Choose from two luxury skin care gift ... delicate eye area or to deliver whole body beauty. ... Duo Gift Set are formulated to suit all skin types ...
(Date:10/1/2014)... 01, 2014 To help raise awareness about ... Cutler Integrative Medicine, is detailing several tips for women looking ... According to Dr. Cutler, women should start each day with ... yourself that will help ‘center’ yourself for the rest of ... says. , Other health and fitness tips include:, -Drink ...
Breaking Medicine News(10 mins):Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3Health News:Long-acting insulin is safer, more effective for patients with Type 1 diabetes 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 2Health News:Éminence Organic Skin Care Launches Limited Edition Spa Gift Sets for the Holiday Season 3Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2
... routinely discarded placenta //might be a good source of stem ... of the journal Stem Cells. ,Researchers had found that ... of the amniotic sac have cells that are very similar ... two genes that make the embryonic stem cells unique in ...
... Researchers from Douglas Hospital Research Center in Montreal showed ... to deal with stressful situations than those who bottle-feed ... well established, this is for the first time findings ... as well. Researchers feel that this is good for ...
... 2005. Hormone Replacement Therapy (HRT) is commonly advocated in ... with increased chances of breast cancer and recently anxiety has ... Medical Journal// the cumulative risk of such a cancer developing ... as was previously reported. ,A team from New ...
... days when drinking was considered to be forbidden. It has ... ,A new research has found that drinking is not all ... reported to have better verbal skills, memory and speed of ... Moderate drinkers not only performed the best but also seemed ...
... wet hair may be far more effective treatment of ... used single blind randomized controlled trial for comparing the ... against head lice in United Kingdom. , ,Fine ... current over the counter chemical treatments for eliminating head ...
... The Food and Drug Administration FDA has recently ... prescription drug advertisements. ,The FDA and the ... practices for drugs, with agency research showing that ... benefits and do not adequately disclose risks. FDA's ...
Cached Medicine News:Health News:Researchers Gather Stem Cells From Discarded Placenta 2Health News:Breastfeeding Lowers Maternal Stress 2Health News:Risk of Breast Cancer Overestimated with Hormone Replacement Therapy(HRT) Treatment 2Health News:Yet Another Reason To Celebrate Drinking 2Health News:Combing Hair More Effective Than OTC Medicine For Head Lice 2
Portable shields for your safety and convenience....
Provide 1.5mm protection throughout. Six durable, attractive vinyl coverings are available. Lead glass window factory installed. Larger window available....
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr...
Front Protection with attached Belt Guard, Built-in Back Support; Buckle Closure...
Medicine Products: